Answers are grounded in this paper and cite their sources.
Purpose of review Homologous recombination repair (HRR) gene alterations are associated with genomic instability and more aggressive prostate cancer (PCa) leading to worse clinical outcomes. poly(ADP-ribose) polymerase inhibitors have demonstrated significant clinical benefit in patients with HRR-altered tumors, and international guidelines now recommend HRR testing. Nevertheless, real-world adoption of this testing remains inconsistent across healthcare systems. To address this gap, we developed expert-driven, practical recommendations for integrating HRR testing into clinical practice for patients with PCa. Recent findings The panel developed consensus recommendations addressing the optimal timing of HRR testing, patient selection criteria, appropriate use of genetic and biomarker testing platforms, and interpretation of test results. Hypothetical case studies illustrated application in clinical settings. These recommendations are evidence-based but reflect expert opinion and should be tailored to local circumstances. No statistical analyses were performed; generalizability may be influenced by differences between healthcare systems. Summary These expert consensus recommendations provide practical guidance on facilitating the broader and more consistent implementation of HRR testing in men with PCa. Wider adoption of such testing may enable more personalized treatment approaches and lead to improved patient outcomes.
No takes yet. Share an insight, caveat, or question.
Shariat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: